📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. Module 2.1 — CTD Table of Contents (OBX-319)

Why it exists. A high-level CTD summary a reviewer reads first; it distils the underlying reports.

How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.

Format & governing standard. —

Module 2.1 — CTD Table of Contents (OBX-319)

Document ID: M21
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4

2.1 CTD Table of Contents

This application comprises the Module 2–5 documents listed below. Module 1 regional administrative content is indexed in the regional Module 1 submission; the Trial Master File, program-management, and quality-system records are maintained outside the eCTD.

Module 2 — CTD Summaries

Module 2.2 — Introduction (OBX-319)
Module 2.3 — Quality Overall Summary (OBX-319)
Module 2.4 — Nonclinical Overview (OBX-319)
Module 2.5 — Clinical Overview (OBX-319)
Module 2.5.6 — Benefit–Risk Assessment (OBX-319)
Module 2.6 — Nonclinical Summaries (OBX-319)
Module 2.7.1 — Summary of Biopharmaceutic Studies (OBX-319)
Module 2.7.2 — Summary of Clinical Pharmacology Studies (OBX-319)
Module 2.7.3 — Summary of Clinical Efficacy (OBX-319)
Module 2.7.4 — Summary of Clinical Safety (OBX-319)
Module 2.7.5 — Literature References (OBX-319)
Module 2.7.6 — Synopses of Individual Studies (OBX-319)

Module 3 — Quality

Module 3 — Analytical Methods Validation (OBX-319)
Module 3 — Appendices & Regional (3.2.A/3.2.R) (OBX-319)
Module 3 — Control Strategy (OBX-319)
Module 3 — Device & Combination Product (OBX-319)
Module 3 — Process Validation (OBX-319)
Module 3 — QTPP & CQA (OBX-319)
Module 3 — Stability Summary (OBX-319)
Module 3.2.P — Drug Product (OBX-319)
Module 3.2.S — Drug Substance (OBX-319)

Module 4 — Nonclinical Study Reports

Module 4.2.1 — Pharmacology (OBX-319)
Module 4.2.2 — Pharmacokinetics (OBX-319)
Module 4.2.3 — Toxicology (OBX-319)
Module 4.3 — Literature References (OBX-319)
SEND / Nonclinical Data Reviewer's Guide (OBX-319)

Module 5 — Clinical Study Reports